Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier drugs, says Christine Johnston.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Dan Nardi of Reimagine Care discusses how to help community practices scale CAR-T programs
2
Closing the outpatient monitoring gap in cancer
3
A conversation with Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, about the relationship between HIV incidence in Hispanic communities and immigration policy
4